Mineralys Therapeutics Soars 12.86% on Positive CKD Trial Data

On June 17, 2025, Mineralys Therapeutics' stock surged by 12.86% in pre-market trading, marking a significant rise in investor confidence.

Mineralys Therapeutics announced positive topline data from its Phase 2 Explore-CKD trial, which evaluated the safety and efficacy of 25 mg of lorundrostat. This trial is a pivotal moment for the company, as it demonstrates the potential of lorundrostat in treating chronic kidney disease, a condition that affects millions of people worldwide.

The positive results from the Phase 2 trial have sparked optimism among investors, who see the potential for lorundrostat to become a groundbreaking treatment. The company's management team is scheduled to host a conference call to discuss the findings in detail, providing further insights into the drug's development and future prospects.